How it works

Affibody^® molecules are a novel class of antibody mimetics with properties that surpass those of monoclonal antibodies (mAbs) and antibody fragments. These small (6kDa), engineered proteins can be conjugated to radioligands, enabling selective targeting of surface proteins on cancer cells and precise delivery of radiation to the tumor site.

Advantages

Affibody’s technology platform offers several key advantages over current approaches, including:

Broad range of targets

Radioligand therapy (RLT) has recently emerged as an exciting cancer treatment modality that can deliver unprecedented improvements in disease control and overall survival. To date, approved RLT drugs have been limited to certain cancer targets in achieving efficacy and safety.

Affibody^® molecules enable highly selective targeting of a broader range of tumor-associated proteins, opening the door to new treatments for solid tumors beyond those currently addressed by RLTs. Our discovery platform includes a library of more than ten billion Affibody^® molecules, each with a unique binding site, from which binders to specific cancer targets are identified and optimized.

Tunable biodistribution

Our Albumod^® linker technology enables association with serum albumin, resulting in a different biodistribution with reduce toxicity.

Radioisotope and chelator agnostic

Site specific modifications create flexibility to tailor to alpha or beta isotopes matching needs of disease.

Developability

Affibody^® molecules have predictable biophysical properties, enabling use of standard scale-up and manufacturing processes. Affibody^® molecules are highly stable, facilitate radioconjugation.

A strong and diversified patent portfolio

An active patent strategy is a precondition for protecting the value of the scientific advances that Affibody delivers. The company has successfully established strong intellectual property protection for its drug candidates in all major geographical markets including the US, the EU, Japan, and other countries.

Our patent portfolio

• Affibody has a portfolio encompassing more than 34 patent families (a patent family is a group of patents and patent applications in different countries that have the same origin).

Our patent strategy

• Concurrent with the scientific advances made in Affibody’s research and development activities, the company regularly submits patent applications to ensure intellectual property and secure potential future earnings.

Our patent longevity

• Affibody’s patents and patent applications provide intellectual property protection into the 2040’s.

Company trademarks

Affibody
“Affibody” is registered in the US, EU, Japan, Australia, Canada, China, Republic of Korea, Switzerland, and United Kingdom.

Albumod
“Albumod” is registered in the US, EU, Japan, China, and United Kingdom.

Company logotype
The Affibody logotype is registered in the US, EU, Japan, Australia, China, Republic of Korea, Switzerland, and United Kingdom, with a pending application in Canada.